Repository logo

Browsing by Author "Jakopovic, Marko"

Now showing 1 - 2 of 2
  • Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study
    Publication . Carugati, Manuela; Aliberti, S.; Sotgiu, G.; Blasi, F.; Gori, A.; Menendez, R.; Encheva, M.; Gallego, M.; Leuschner, P.; Ruiz-Buitrago, S.; Battaglia, S.; Fantini, R.; Pascual-Guardia, S.; Marin-Corral, J.; Restrepo, M. I.; Aruj, Patricia Karina; Attorri, Silvia; Barimboim, Enrique; Caeiro, Juan Pablo; Garzón, María I; Cambursano, Victor Hugo; Ceccato, Adrian; Chertcoff, Julio; Lascar, Florencia; Tulio, Fernando Di; Díaz, Ariel Cordon; de Vedia, Lautaro; Ganaha, Maria Cristina; Lambert, Sandra; Lopardo, Gustavo; Luna, Carlos M; Malberti, Alessio Gerardo; Morcillo, Nora; Tartara, Silvina; Pensotti, Claudia; Pereyra, Betiana; Scapellato, Pablo Gustavo; Stagnaro, Juan Pablo; Shah, Sonali; Lötsch, Felix; Thalhammer, Florian; Vincent, Jean Louis; Anseeuw, Kurt; Francois, Camille A; Van Braeckel, Eva; Djimon, Marcel Zannou; Bashi, Jules; Roger, Dodo; Nouér, Simone Aranha; Chipev, Peter; Encheva, Milena; Miteva, Darina; Petkova, Diana; Dodo, Balkissou Adamou; Ngahane, Mbatchou; Hugo, Bertrand; Shen, Ning; Xu, Jin-fu; Rico, Carlos Andres Bustamante; Buitrago, Ricardo; Paternina, Fernando Jose Pereira; Jean-Marie, Kayembe Ntumba; Carevic, Vesna Vladic; Jakopovic, Marko; Jankovic, Mateja; Matkovic, Zinka; Mitrecic, Ivan; Jacobsson, Marie-Laure Bouchy; Christensen, Anette Bro; HeitmannBødtger, Uff e Christian; Meyer, Christian Niels; Jensen, Andreas Vestergaard; Baunbæk-knudsen, Gertrud; Petersen, Pelle Trier; Andersen, Stine; El-Wahhab, Ibrahim El-Said Abd; Morsy, Nesreen Elsayed; Shafiek, Hanaa; Sobh, Eman; Bertrand, Fabrice; Brun-Buisson, Christian; de Montmollin, Etienne; Fartoukh, Muriel; Messika, Jonathan; Tattevin, Pierre; Dreher, Michael; Kolditz, Martin; Meisinger, Matthias; Pletz, Mathias W; Hagel, Stefan; Rupp, Jan; Schaberg, Tom; Spielmanns, Marc; Siaw-Lartey, Beatrice; Dimakou, Katerina; Papapetrou, Dimosthenis; Tsigou, Evdoxia; Ampazis, Dimitrios; Bhatia, Mohit; Dhar, Raja; D’Souza, George; Garg, Rajiv; Koul, Parvaiz A; Mahesh, P A; Jayaraj, B S; Narayan, Kiran Vishnu; Udnur, Hirennappa B; Krishnamurthy, Shashi Bhaskara; Golshani, Keihan; Keatings, Vera M; Martin-Loeches, Ignacio; Maor, Yasmin; Strahilevitz, Jacob; Battaglia, Salvatore; Carrabba, Maria; Ceriana, Piero; Confalonieri, Marco; d’Arminio Monforte, Antonella; Del Prato, Bruno; De Rosa, Marino; Fantini, Riccardo; Fiorentino, Giuseppe; Gammino, Maria Antonia; Menzella, Francesco; Milani, Giuseppe; Nava, Stefano; Palmiero, Gerardo; Petrino, Roberta; Gabrielli, Barbra; Rossi, Paolo; Sorino, Claudio; Steinhilber, Gundi; Zanforlin, Alessandro; Kurahashi, Kiyoyasu; Bacha, Zeina Aoun; Ugalde, Daniel Barajas; Zuñiga, Omar Ceballos; Villegas, José F; Medenica, Milic; van de Garde, E M W; Mihsra, Deebya Raj; Shrestha, Poojan; Ridgeon, Elliott; Awokola, Babatunde Ishola; Nwankwo, Ogonna N O; Olufunlola, Adefuye Bolanle; Olumide, Segaolu; Ukwaja, Kingsley N; Irfan, Muhammad; Minarowski, Lukasz; Szymon, Skoczyński; Froes, Felipe; Leuschner, Pedro; Meireles, Mariana; Ferrão, Cláudia; Leuschner, Pedro; Neves, João; Ravara, Sofia B; da Beira, Cova; Brocovschii, Victoria; Ion, Chesov; Rusu, Doina; Toma, Cristina; Chirita, Daniela; Birkun, Alexei; Kaluzhenina, Anna; Almotairi, Abdullah; Abdulbaqi, Zakeya; Bukhary, Ali; Edathodu, Jameela; Fathy, Amal; Enani, Abdullah Mushira Abdulaziz; Mohamed, Nazik Eltayeb; Memon, Jawed Ulhadi; Bogdanović, Nada; Milenkovic, Branislava; Pesut, Dragica; Borderìas, Luis; Garcia, Noel Manuel Bordon; Alarcón, Hugo Cabello; Cilloniz, Catia; Torres, Antoni; Diaz-Brito, Vicens; Casas, Xavier; González, Alicia Encabo; Fernández-Almira, Maria Luisa; Gallego, Miguel; Gaspar-GarcÍa, Inmaculada; del Castillo, Juan González; Victoria, Patricia Javaloyes; Martínez, Elena Laserna; de Molina, Rosa Malo; Marcos, Pedro J; Menéndez, Rosario; PandoSandova, Ana; Aymerich, Cristina Prat; del la Torre, Alicia Lacoma; García-Olivé, Ignasi; Rello, Jordi; Moyano, Silvia; Sanz, Francisco; Sibila, Oriol; Rodrigo-Troyano, Ana; Solé-Violán, Jordi; Uranga, Ane; van Boven, Job FM; Torra, Ester Vendrell; Pujol, Jordi Almirall; Feldman, Charles; Yum, Ho Kee; Fiogbe, Arnauld Attannon; Yangui, Ferdaous; Bilaceroglu, Semra; Dalar, Levent; Yilmaz, Ufuk; Bogomolov, Artemii; Elahi, Naheed; Dhasmana, Devesh J; Ions, Rhiannon; Skeemer, Julie; Woltmann, Gerrit; Hancock, Carole; Hill, Adam T; Rudran, Banu; Ruiz-Buitrago, Silvia; Campbell, Marion; Whitaker, Paul; Allen, Karen S; Brito, Veronica; Dietz, Jessica; Dysart, Claire E; Kellie, Susan M; Franco-Sadud, Ricardo A; Meier, Garnet; Gaga, Mina; Holland, Thomas L; Bergin, Stephen P; Kheir, Fayez; Landmeier, Mark; Lois, Manuel; Nair, Girish B; Patel, Hemali; Reyes, Katherine; Rodriguez-Cintron, William; Saito, Shigeki; Soni, Nilam J; Noda, Julio; Hinojosa, Cecilia I; Levine, Stephanie M; Angel, Luis F; Anzueto, Antonio; Whitlow, K Scott; Hipskind, John; Sukhija, Kunal; Wunderink, Richard G.; Shah, Ray D; Mateyo, Kondwelani John
    An accurate knowledge of the epidemiology of community-acquired pneumonia (CAP) is key for selecting appropriate antimicrobial treatments. Very few etiological studies assessed the appropriateness of empiric guideline recommendations at a multinational level. This study aims at the following: (i) describing the bacterial etiologic distribution of CAP and (ii) assessing the appropriateness of the empirical treatment recommendations by clinical practice guidelines (CPGs) for CAP in light of the bacterial pathogens diagnosed as causative agents of CAP. Secondary analysis of the GLIMP, a point-prevalence international study which enrolled adults hospitalized with CAP in 2015. The analysis was limited to immunocompetent patients tested for bacterial CAP agents within 24 h of admission. The CAP CPGs evaluated included the following: the 2007 and 2019 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA), the European Respiratory Society (ERS), and selected country-specific CPGs. Among 2564 patients enrolled, 35.3% had an identifiable pathogen. Streptococcus pneumoniae (8.2%) was the most frequently identified pathogen, followed by Pseudomonas aeruginosa (4.1%) and Klebsiella pneumoniae (3.4%). CPGs appropriately recommend covering more than 90% of all the potential pathogens causing CAP, with the exception of patients enrolled from Germany, Pakistan, and Croatia. The 2019 ATS/IDSA CPGs appropriately recommend covering 93.6% of the cases compared with 90.3% of the ERS CPGs (p < 0.01). S. pneumoniae remains the most common pathogen in patients hospitalized with CAP. Multinational CPG recommendations for patients with CAP seem to appropriately cover the most common pathogens and should be strongly encouraged for the management of CAP patients.
    2020Journal article Open access Show more
  • Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
    Publication . Janzic, Urska; Shalata, Walid; Szymczak, Katarzyna; Dziadziuszko, Rafał; Jakopovic, Marko; Mountzios, Giannis; Płużański, Adam; A, Araujo; Charpidou, Andriani; Agbarya, Abed
    BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83).
    2023-08Journal article Open access Show more